Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23 | Free Publication Certificate
NAAS Rating: 5.23 new

Vol. 10, Issue 6 (2021)

Why not methylene blue over the HCQ and remdesvir

Bhavesh B Patel
Severity of COVID – 19 pandemic discourse the novel treatment and approach against viral infection. Repurposing of various drugs are exercised to treat the corona infection. Available resources of drugs are not targeting the key ligands of the virus and host interaction. Methylene blue is widely utilized to treat the patients of COVID – 19 in India. In silico approach attracted the focus to study its role in binding with different proteins involved in infection. Total ten different proteins were selected to study the efficiency binding of methylene blue. Docking study revealed favorable binding score of methylene blue against the studied proteins. Present study disclosed the methylene blue as a promising molecule to treat the infectivity of virus, after confirmation through in vitro and in vivo study.
Pages: 07-08  |  521 Views  95 Downloads

The Pharma Innovation Journal
How to cite this article:
Bhavesh B Patel. Why not methylene blue over the HCQ and remdesvir. Pharma Innovation 2021;10(6):07-08. DOI: 10.22271/tpi.2021.v10.i6a.6746
Important Publications Links
The Pharma Innovation Journal

The Pharma Innovation Journal

Call for book chapter
The Pharma Innovation Journal